Search Results - "Clair, Phillip M"

Sox2 Cooperates with Lkb1 Loss in a Mouse Model of Squamous Cell Lung Cancer by Mukhopadhyay, Anandaroop, Berrett, Kristofer C., Kc, Ushma, Clair, Phillip M., Pop, Stelian M., Carr, Shamus R., Witt, Benjamin L., Oliver, Trudy G.

“…Squamous cell carcinoma (SCC) of the lung is the second most common subtype of lung cancer. With limited treatment options, the 5-year survival rate of SCC is…”
Get full text

Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion by Heaton, William L., Senina, Anna V., Pomicter, Anthony D., Salama, Mohamed E., Clair, Phillip M., Yan, Dongqing, Bell, Russell N., Gililland, Jeremy M., Prchal, Josef T., O’Hare, Thomas, Deininger, Michael W.

“…Tumor necrosis factor alpha (TNF) is increased in myelofibrosis (MF) and promotes survival of malignant over normal cells. The mechanisms altering TNF…”
Get full text

BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia by Antelope, Orlando, Vellore, Nadeem A., Pomicter, Anthony D., Patel, Ami B., Van Scoyk, Alexandria, Clair, Phillip M., Deininger, Michael W., O'Hare, Thomas

“…•K0706 is a BCR-ABL1 tyrosine kinase inhibitor under clinical investigation in CML.•K0706 exhibits in vitro activity against most clinically important BCR-ABL1…”
Get full text

SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA by Yan, Dongqing, Franzini, Anca, Pomicter, Anthony D, Halverson, Brayden J, Antelope, Orlando, Mason, Clinton C, Ahmann, Jonathan M, Senina, Anna V, Vellore, Nadeem A, Jones, Courtney L, Zabriskie, Matthew S, Than, Hein, Xiao, Michael J, van Scoyk, Alexandria, Patel, Ami B, Clair, Phillip M, Heaton, William L, Owen, Shawn C, Andersen, Joshua L, Egbert, Christina M, Reisz, Julie A, D'Alessandro, Angelo, Cox, James E, Gantz, Kevin C, Redwine, Hannah M, Iyer, Siddharth M, Khorashad, Jamshid S, Rajabi, Nima, Olsen, Christian A, O'Hare, Thomas, Deininger, Michael W

“…We discovered that the survival and growth of many primary acute myeloid leukemia (AML) samples and cell lines, but not normal CD34+ cells, are dependent on…”
Get full text

MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis by Zhao, Helong, Pomicter, Anthony D., Eiring, Anna M., Franzini, Anca, Ahmann, Jonathan, Hwang, Jae-Yeon, Senina, Anna, Helton, Bret, Iyer, Siddharth, Yan, Dongqing, Khorashad, Jamshid S., Zabriskie, Matthew S., Agarwal, Anupriya, Redwine, Hannah M., Bowler, Amber D., Clair, Phillip M., McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W., Stirewalt, Derek L., Oehler, Vivian G., Varambally, Sooryanarayana, Berrett, Kristofer C., Vahrenkamp, Jeffery M., Gertz, Jason, Varley, Katherine E., Radich, Jerald P., Deininger, Michael W.

“…The chronic phase of chronic myeloid leukemia (CP-CML) is characterized by the excessive production of maturating myeloid cells. As CML stem/progenitor cells…”
Get full text

Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis by Yan, Dongqing, Pomicter, Anthony D, Tantravahi, Srinivas, Mason, Clinton C, Senina, Anna V, Ahmann, Jonathan M, Wang, Qiang, Than, Hein, Patel, Ami B, Heaton, William L, Eiring, Anna M, Clair, Phillip M, Gantz, Kevin C, Redwine, Hannah M, Swierczek, Sabina I, Halverson, Brayden J, Baloglu, Erkan, Shacham, Sharon, Khorashad, Jamshid S, Kelley, Todd W, Salama, Mohamed E, Miles, Rodney R, Boucher, Kenneth M, Prchal, Josef T, O'Hare, Thomas, Deininger, Michael W

“…Myelofibrosis is a hematopoietic stem cell neoplasm characterized by bone marrow reticulin fibrosis, extramedullary hematopoiesis, and frequent transformation…”
Get full text

Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells by Than, Hein, Pomicter, Anthony D., Yan, Dongqing, Beaver, Larry P., Eiring, Anna M., Heaton, William L., Senina, Anna, Clair, Phillip M., Shacham, Sharon, Mason, Clinton C., Hare, Thomas O’, Deininger, Michael W.

Get full text

Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine by Wang, Jiawei, Li, Lian, Yang, Jiyuan, Clair, Phillip M., Glenn, Martha J., Stephens, Deborah M., Radford, D. Christopher, Kosak, Ken M., Deininger, Michael W., Shami, Paul J., Kopeček, Jindřich

“…Drug-free macromolecular therapeutics (DFMT) is a new paradigm for the treatment of B cell malignancies. Apoptosis is initiated by the biorecognition of…”
Get full text

BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits pre-clinical activity in Philadelphia chromosome-positive leukemia by Antelope, Orlando, Vellore, Nadeem, Pomicter, Anthony D, Patel, Ami B, van Scoyk, Alexandria, Clair, Phillip M, Deininger, Michael, O'Hare, Thomas

“…Highlights•• K0706 is BCR-ABL1 tyrosine kinase inhibitor under clinical investigation in CML. •• K0706 exhibits in vitro activity against most clinically…”
Get full text

Femoral Heads from Total Hip Arthroplasty as a Source of Adult Hematopoietic Cells by Pomicter, Anthony D, Clair, Phillip M, Yan, Dongqing, Heaton, William L, Eiring, Anna M, Anderson, Michael B, Richards, Stephen M, Gililland, Jeremy, O'Hare, Thomas, Deininger, Michael W

“…Normal human bone marrow cells are critical for studies of hematopoiesis and as controls to assess toxicity. As cells from commercial vendors are expensive,…”
Get more information

Drug-Free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction By Pretreatment with Gemcitabine by Wang, Jiawei, Li, Lian, Yang, Jiyuan, Clair, Phillip M., Glenn, Martha, Stephens, Deborah M., Radford, D. Christopher, Kosak, Ken M., Deininger, Michael W., Shami, Paul J, Kopeček, Jindřich

“…Background Anti-CD20 mAbs are an important element in the therapeutic armamentarium for B-cell malignancies such as chronic lymphocytic leukemia (CLL)…”
Get full text

MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common β Chain Cytokine Receptor Endocytosis by Zhao, Helong, Pomicter, Anthony D., Eiring, Anna M., Franzini, Anca, Ahmann, Jonathan, Hwang, Jae-Yeon, Senina, Anna V., Helton, Bret, Iyer, Siddharth, Yan, Dongqing, Khorashad, Jamshid, Zabriskie, Matthew S., Agarwal, Anupriya, Redwine, Hannah M, Bowler, Amber D., Clair, Phillip M., McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W., Stirewalt, Derek, Oehler, Vivian G., Varambally, Sooryanarayana, Berrett, Kristofer, Vahrenkamp, Jeffrey, Gertz, Jason, Varley, Katherine, Radich, Jerald P., Deininger, Michael W.

“…Background Chronic phase chronic myeloid leukemia (CP-CML) is characterized by overproduction of differentiating myeloid cells, while blast phase CML (BP-CML)…”
Get full text

Evaluation of an Automated Immunoassay for Quantification of Imatinib in Plasma by Tantravahi, Srinivas K., McMillin, Gwendolyn A., Clair, Phillip M., Sadler, Aaron J., Dowell, Tracy, Geier, Janice, Bernard, Philip S., Deininger, Michael W.

“…Imatinib mesylate is a first-line tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia (CML). Therapeutic drug monitoring (TDM) of…”
Get full text

SIRT5 As a Therapeutic Target in Acute Myeloid Leukemia by Yan, Dongqing, Pomicter, Anthony D., Heaton, William L., Mason, Clint C., Ahmann, Jonathan, Senina, Anna, Franzini, Anca, Halverson, Brayden, Than, Hein, Clair, Phillip M., Khorashad, Jamshid S, O'Hare, Thomas, Deininger, Michael W.

“…Acute myeloid leukemia (AML) is an aggressive hematopoietic neoplasm with five-year overall survival rates <30% on standard of care therapy. Relapse is common…”
Get full text

Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants by Eide, Christopher A., Zabriskie, Matthew S., Savage, Samantha L., Antelope, Orlando, Vellore, Nadeem A., Than, Hein, Reister Schultz, Anna, Clair, Phillip M., Bowler, Amber D., Pomicter, Anthony D., Yan, Dongqing, Senina, Anna V., Wang, Qiang, Kelley, Todd W., Szankasi, Philippe, Heinrich, Michael C., Tyner, Jeffrey W., Rea, Delphine, Cayuela, Jean-Michel, Kim, Dong-Wook, Tognon, Cristina E., O'Hare, Thomas, Druker, Brian J., Deininger, Michael W.

“…▪ BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-positive (Ph+) leukemia is effectively…”
Get full text

Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia by Than, Hein, Pomicter, Anthony D., Mason, Clinton C., Eiring, Anna M., Heaton, William L., Yan, Dongqing, Senina, Anna, Clair, Phillip M., Holyoake, Tessa L., O'Hare, Thomas, Deininger, Michael W.

“…Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy driven by BCR-ABL1 tyrosine kinase and effectively managed with tyrosine kinase…”
Get full text

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia by Eiring, A M, Khorashad, J S, Anderson, D J, Yu, F, Redwine, H M, Mason, C C, Reynolds, K R, Clair, P M, Gantz, K C, Zhang, T Y, Pomicter, A D, Kraft, I L, Bowler, A D, Johnson, K, Partlin, M Mac, O'Hare, T, Deininger, M W

“…Activation of nuclear β-catenin and expression of its transcriptional targets promotes chronic myeloid leukemia (CML) progression, tyrosine kinase inhibitor…”
Get full text

Selective Inhibition of Nuclear Cytoplasmic Transport As a New Treatment Paradigm in Myelofibrosis by Yan, Dongqing, Tantravahi, Srinivas K., Pomicter, Anthony D., Senina, Anna, Gantz, Kevin C., Redwine, Hannah M., Prchal, Josef T., Swierczek, Sabina, Clair, Phillip M., Eiring, Anna M., Baloglu, Erkan, O'Hare, Thomas, Deininger, Michael W.

“…▪ Myelofibrosis (MF) is a hematopoietic stem cell neoplasm characterized by constitutive activation of JAK/STAT signaling due to mutations in JAK2,…”
Get full text

Selective Inhibition of Nucleocytoplasmic Transport Overcomes Ruxolitinib Resistance in Myelofibrosis by Yan, Dongqing, Tantravahi, Srinivas K., Pomicter, Anthony D., Mason, Clinton C., Senina, Anna, Wang, Qiang, Sorouri Khorashad, Jamshid, Than, Hein, Clair, Phillip M., Heaton, William L., Eiring, Anna M., Prchal, Josef T., Swierczek, Sabina I., Baloglu, Erkan, Shacham, Sharon, O'Hare, Thomas, Deininger, Michael W.

“…Myelofibrosis (MF) is a stem cell-derived hematopoietic malignancy characterized by constitutive activation of JAK/STAT signaling through mutations in JAK2,…”
Get full text

MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia by Eiring, Anna M., Khorashad, Jamshid S., Agarwal, Anupriya, Mason, Clinton C., Bell, Russell, Senina, Anna, Pomicter, Anthony D., Yu, Fan, Redwine, Hannah M., Bowler, Amber D., Clair, Phillip M., Tantravahi, Srinivas K., McWeeney, Shannon K., Druker, Brian J., Stirewalt, Derek L., Oehler, Vivian, O'Hare, Thomas, Deininger, Michael W.

“…Background: We have previously demonstrated that the transcriptional profile of diagnostic CD34+ cells from chronic phase chronic myeloid leukemia (CP-CML)…”
Get full text